The non-nucleoside reverse transcriptase (RT) inhibitor RD4-2217 is a thiadiazole derivative that has proved to be a highly potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) replication in vitro. In this study we exam- 
The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is essential for its replication. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) suppress HIV-1 replication by binding at a hydrophobic pocket in the palm domain of the p66 subunit (Tantillo et al., 1994; Spence et al., 1995) . Several classes of compounds have been identified as NNRTIs, which include TIBO derivatives (Pauwels et al., 1990) , 1-(2-hydroxyethoxymethyl)6-(phenylthio)thymine (HEPT) and its derivatives (Baba et al., 1989 (Baba et al., , 1991 , nevirapine (Merluzzi et al., 1990) , pyridinone derivatives (Goldman et al., 1991) , bis(heteroaryl)piperazines (BHAP) (Romero et al., 1991) , α-anilinophenylaxetamides (α-APA) (Pauwels et al., 1993) and phenylethylthioureathiazole (PETT) derivatives (Ahgren et al., 1995) . Among the NNRTIs, nevirapine, delavirdine (Davey et al., 1996) and efavirenz (Young et al., 1995) have currently been approved for the treatment of AIDS patients.
Although NNRTIs are highly potent and selective inhibitors of HIV-1 replication, rapid emergence of drug resistance is a major concern during treatment with this class of compounds. Resistance is mediated by amino acid mutations within the binding pocket of HIV-1 RT, including A98G, L100I, K101E, K103N, V106A, V108I, E138K, T139I, G141E, V179D, Y181C, Y188C, V189I, G190A, E233V, P236L and K238T (Schinazi et al., 1996) . In particular, the K103N and Y181C mutations confer cross-resistance to most of the NNRTIs (Richman et al., 1994; Demeter et al., 1997 (Young et al., 1995) . S-1153 (AG-1549) was also inhibitory to the replication of various RT mutants having a variety of single amino acid substitutions, including K103N and Y181C (Fujiwara et al., 1998) . Similar to efavirenz, a double mutation (V106A plus F227L) was needed to generate high-level resistance to S-1153. We have previously reported that thiadiazole derivatives are highly potent and selective inhibitors of HIV-1 replication in vitro and that they belong to a family of NNRTIs (Ijichi et al., 1995) . Synthesis of a large number of thiadiazole derivatives followed by structure-activity relationship (SAR) studies has achieved significant improvement in the anti-HIV-1 activity of thiadiazole derivatives. Among them, RD4-2217 was found to be the most potent inhibitor, and it could completely inhibit viral breakthrough from HIV-1-infected cells at relatively high concentrations (1-10 µM) in long-term cultures. In addition, the combination of a low concentration of RD4-2217 (10 or 100 nM) and zidovudine (100 nM) completely suppressed viral replication for a 3 month culture period (Fujiwara et al., 1997) . Accordingly, the compound could be a promising candidate for the treatment of HIV-1-infected individuals. In this study, we report the genotypic and phenotypic analysis of RD4-2217-resistant strains obtained through a serial passage of HIV-1-infected cells.
Materials and Methods

Compounds
RD4-2217 and loviride were synthesized by Tokyo Research Laboratories (Tosoh, Kanagawa, Japan) ( Figure  1 ). 3′-Azido-3′-deoxythymidine (zidovudine) was purchased from Sigma. The test compounds were dissolved in DMSO at appropriate concentrations and stored at -20°C until use. The final concentration of DMSO was always less than 1% (v/v) in culture medium.
Cells and viruses
MT-4 cells (Miyoshi et al., 1982) were used in antiviral assays. The cells were mycoplasma-negative. MT-4 cells were grown and maintained in RPMI-1640 medium supplemented with 10% heat-inactivated foetal calf serum (hi-FCS), 100 U/ml penicillin G and 100 µg/ml streptomycin. HIV-1 (III B and III B-R strains) was used in the assays. III B-R , which has a single amino acid mutation (Y181C) in the RT, is a NNRTI-resistant mutant established by a serial passage of infected cells in the presence of increasing concentrations of MKC-442 (Baba et al., 1994) . MKC-442 is under Phase II clinical trials now. Titres of virus stocks were determined by the 50% tissue culture infective dose method in MT-4 cells, and the stocks were stored at -80°C until use.
Infectious molecular clones with the substitution of amino acids, either K103N, V106A, V108I, E138K, Y181C, V189I, T240I or V189I plus T240I, in the RT were obtained by site-directed mutagenesis of pSUM9 derived from the pHXB2RIP-7 plasmid, as previously described (Maeda et al., 1998) . COS-7 cells were transfected with 15 µg of the obtained DNA clone by a calcium phosphate method and cultured for 48 h. Progeny viruses were propagated in MT-2 cells and subsequently in H9 cells for 7 days. Culture supernatants were stored at -80°C until use, and the infectivity of virus stocks was determined in the multinuclear activation of galactosidase indicator (MAGI) assay (Kimpton et al., 1992) .
Selection of drug-resistant mutants
Resistant viruses were selected in cell culture by serial passage of HIV-1 III B strain-infected MT-4 cells in the presence of increasing concentrations of test compounds. Briefly, MT-4 cells were infected with the virus at a multiplicity of infection (m.o.i.) of 0.02. The infected cells were incubated at 37°C in the presence of compounds at a concentration of 0.05 µM and passaged every 3 or 4 days with fresh culture medium containing the same concentration of compounds. When HIV-1-induced syncytia were observed in most of the cell cultures, the culture supernatants were collected and used for new infection of MT-4 cells. Then, 
Antiviral assays
The antiviral activities of the compounds against the replication of HIV-1 mutants were based on the inhibition of virus-induced cytopathic effect in MT-4 cells. Briefly, MT-4 cells were suspended in culture medium at 1×10 5 cells/ml and infected with HIV-1 at a m.o.i. of 0.02. Immediately after virus infection, the cell suspension (100 µl) was added to each well of a flat-bottomed 96-well plate containing various concentrations of the test compounds. After a 5 day incubation period at 37°C, the number of viable cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels et al., 1988) . The cytotoxic effect of the compounds was evaluated in parallel with the antiviral activity. These assays were based on the viability of mock-infected cells determined by the MTT method.
The antiviral activities of the compounds against the replication of various molecular clones were based on the inhibition of virus-induced focus formation in HeLa-CD4-LTR/β-gal (MAGI-HeLa) cells. Briefly, MAGIHeLa cells were cultured semi-confluently in each well of a flat-bottomed 96-well plate and infected with the virus at 50 f.f.u./well. Immediately after virus infection, the infected cells were cultured in the presence of various concentrations of the compounds. After a 2 day incubation period at 37°C, the number of infected (blue) cells was determined microscopically (Maeda et al., 1998) . The cytotoxic effect of the compounds was evaluated by the MTT method.
RT sequencing
MT-4 cells (1×10 6 cells) were infected with the HIV-1 mutants at a m.o.i. of 0.02 and cultured for 2 days. Total DNA from the infected cells was extracted by a nucleic acid extraction kit (Iso Quick, MicroProbe, Bothell, Wash., USA). The RT region was amplified with primer pairs RT18/21 (Herzberg et al., 1995) by PCR. Direct sequencing of the amplified products was performed with the IRD41-labelled primer (RT19 or RT20) (Herzberg et al., 1995) and SequiTherm sequencing kit (Epicenter Technology, Lincoln, Nebr., USA) using an automatic sequencer (LI-COR, Lincoln, Nebr., USA). The codons between 1 and 250 of the RT were determined.
Replication kinetics
The replication kinetics of HIV-1 mutants were determined by p24 antigen production in MT-4 cells. In this experiment the cells were infected with 2 ng (p24) of HIV-1 per ml. After 2 h viral adsorption the cells were extensively washed to remove unadsorbed virus particles and incubated at 37°C. On days 1, 3, 5 and 7 after virus infection, the amount of p24 antigen in culture supernatants was measured by a p24 antigen-capture ELISA kit (Cellular Products, Buffalo, NY., USA).
Results
When we examined the antiviral activities of RD4-2217, loviride and zidovudine against HIV-1 replication in MT-4 cells, RD4-2217 inhibited the replication of the wildtype III B with a 50% effective concentration (EC 50 ) of 0.042 µM (Table 1) . Loviride and zidovudine also inhibited the III B strain, and the EC 50 values were 0.046 and 0.003 µM, respectively. On the other hand, RD4-2217 was 114-fold less inhibitory to the MKC-442-resistant strain (Table 2) . Mutations were observed for the highly resistant strains III B/2217RE/1 and III B/2217RE/10 . Both of them had V189I and T240I substitutions in the RT (Table  2) . These mutations were not identified for the strains highly resistant to loviride (III B/LovRE/1 and III B/LovRE/10 ), and they had the Y181C mutation in RT (Table 2) . We also identified the Y181C mutation of an RD4-2217-resistant strain in another experiment (data not shown).
Inhibitory effects of RD4-2217 on the replication of molecular clones having various amino acid changes in the RT are shown in Table 3 . The single amino acid substitutions of either K103N, V106A, V108I, E138K or V189I, Table 3 . Inhibitory effects of RD4-2217, loviride and the zidovudine on replication of molecular clones with RT mutation in MAGI cells affected little, if any, of the anti-HIV-1 activities of RD4-2217. However, the activity against T240I, Y181C and V189I plus T240I mutants was 10-, 84-and >526-fold weaker than that against the wild-type, respectively. Consequently, the double mutation (V189I plus T240I) conferred complete resistance to RD4-2217 on the molecular clone (EC 50 >10 µM). In contrast to RD4-2217, the K103N and V108I mutations considerably affected the anti-HIV-1 activities of loviride. The replication of III B , III B-R , the RD4-2217-resistant strains and the loviride-resistant strains, was evaluated by the production of p24 antigen in culture supernatants of the infected MT-4 cells. The p24 antigen levels of III B/2217RE/1 -and III B/2217RE/10 -infected cell cultures were lower than those of III B -and III B-R -infected cell cultures on days 5 and 7 after viral infection (Figure 2 ). There was no substantial difference in p24 antigen levels among the III B/2217RE/0.05 -, III B/2217RE/0.25 -, III B -and III B-R -infected cell cultures. The replication of III B/LovRE/1 and III B/LovRE/10 appeared to be as efficient as that of III B and III B-R at least until day 5 (Figure 2 ). These results suggest that the V189I and T240I mutations may impair the enzymatic activity of HIV-1 RT.
Discussion
We have previously reported the thiadiazole derivatives as novel HIV-1-specific RT inhibitors (Fujiwara et al., 1997; Ijichi et al., 1995) . Studies of the mechanism of action have revealed that the thiadiazole derivatives belong to the family of NNRTIs (Ijichi et al., 1996) . In this report, we evaluated the genotypic and phenotypic changes of RD4-2217-resistant strains. Because of a structural similarity between RD4-2217 and loviride, HIV-1 strains with reduced susceptibility to RD4-2217 and loviride were selected using cell culture system in the presence of escalating concentrations of the compounds.
We did not detect any mutations in the RT (codon 1-250) of III B/2217RE/0.05 and III B/2217RE/0.25 , yet both mutants showed two-and 15-fold resistance to RD4-2217, and 54-and 126-fold reduced sensitivity to loviride (Tables 1 and  2 ). The same phenomena was observed for III B/lovirideRE/0.05 and III B/lovirideRE/0.25 . These results indicate that the compounds may induce the mutations of the RT outside the position of 250, and the mutation may influence on the anti-HIV-1 activity of RD4-2217 and loviride.
We found that both V189I and the novel mutation T240I were necessary for high-level resistance to RD4-2217 (Table 2) . On the other hand, we could only identify the Y181C mutation in the RT of the mutants highly resistant to loviride. These observations were confirmed by the experiments using molecular clones with site-directed RT mutations (Table 3) . Furthermore, we also demonstrated that the resistance profiles of RD4-2217 to these molecular clones differed from those of loviride, suggesting that the binding site of RD4-2217 to the HIV-1 RT does not completely overlap with that of loviride.
The nevirapine-resistant virus was found to be stable over a period of 2 years in the absence of nevirapine treatment (Imrie et al., 1997) . Similarly, Miller et al. (1998) also reported that the K103N-associated resistance to loviride remained stable in the patients who had discontinued the treatment with loviride after 8 to 27 months. Thus, if NNRTI resistance exists due to the failure of prior NNRTI therapy, subsequent treatment with another NNRTI may not be successful. In this regard, however, we found in this study that the mutants highly resistant to RD4-2217 (III B/2217RE/1 and III B/2217/10 ) replicated less efficiently in MT-4 cells (Figure 2) . These results suggest that V189I plus T240I mutation in RT may reduce the enzymatic activity. Although it is still unclear whether this observation is also applicable in vivo, RD4-2217 should be further pursued for its chemotherapeutic potential for HIV-1 infection.
